COVID-19 Pandemic Means Another Delay For Canadian Pricing Reforms
Industry has have welcomed another delay to the implementation of drug pricing reforms that aim to lower Canadian drugs prices.
You may also be interested in...
This month, long-awaited new pricing measures in Canada will come into force, while several trials will either kick off or end, including a liability opioids case involving Teva in San Francisco and Hatch-Waxman litigation over Otsuka/Lundbeck’s Rexulti.
Some measures aimed at reducing medicine prices in Canada have been dropped, to the relief of the pharmaceutical industry.
A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.